Glasgow Precision Oncology Laboratory (GPOL) was established in 2016 to advance novel therapeutic strategies for cancer for research and industry. GPOL’s purpose built capacity, expertise, infrastructure and resources are aligned in order to accelerate therapeutic development from discovery through to preclinical and clinical development.
GPOL supports researchers and industry with molecular tests and laboratory experiments to develop better cancer treatments. This includes tests for discovery work on patient tumours, including Next Generation Sequencing and RNASeq; and experiments to understand models of disease, through defining the genomic mutational landscape and then through providing molecular phenotypes for clinical trials development.
Through the University of Glasgow GPOL can also offer training to clinicians, PhD and Masters students.
While GPOL has extensive expertise in pancreatic cancer, it also works with other cancer types including colorectal, ovarian, brain and liver cancer.
GPOL (through University of Glasgow) is part of the Scottish Precision Medicine Ecosystem, which networks numerous national efforts in precision medicine for all disease, including the Stratified Medicine Scotland Innovation Centre and the Scottish Genomes Partnership. GPOL is also linked to the Imaging Centre of Excellence (ICE) at the NHS Greater Glasgow and Clyde Queen Elizabeth University Hospital for advanced molecular and image analysis.
The PrecisionPanc platform is a case study of how GPOL’s divisions are integrated to enable the delivery of precision oncology into the NHS for pancreatic cancer patients.